The landscape of reconstructive and aesthetic surgery is poised for a technological transformation as the American Society of Plastic Surgeons (ASPS) and the globally recognized MedTech Innovator (MTI) program announce the five startups selected for the 2026 Plastic Surgery specialty track. This strategic partnership, now entering its fifth year, serves as a high-stakes incubator designed to fast-track medical devices, diagnostic tools, and digital health solutions from the conceptual phase to clinical implementation.
As the industry faces a surge in demand for minimally invasive procedures, personalized medicine, and AI-driven diagnostics, the role of these startups becomes increasingly critical. The 2026 cohort—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—emerged from a highly competitive pool of 135 applicants, representing the most promising potential to redefine patient outcomes in the years to come.
Main Facts: The 2026 ASPS Plastic Surgery Track
The selection of these five startups is not merely an accolade; it is an entry point into a rigorous ecosystem of development. The 2026 MedTech Innovator program functions as a catalyst for early- to mid-stage companies, providing the infrastructure, mentorship, and financial visibility required to navigate the complex regulatory and commercial pathways of the medical technology industry.
The selected companies—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—are now part of a larger, elite group of 65 startups participating in the broader MTI accelerator. Collectively, these companies are vying for a total prize pool of $800,000 in non-dilutive funding, with the ultimate winners set to be unveiled this autumn at the prestigious MedTech Conference in Boston.
Beyond the capital, the true value for these five firms lies in the integration with the ASPS community. By bridging the gap between innovative engineering and clinical expertise, the program ensures that technological advancements are not only theoretically sound but practically applicable in the operating room.
Chronology of Selection: From Application to Acceleration
The journey to becoming one of the "ASPS Five" is a grueling process that mirrors the high standards of medical innovation.
The Call for Innovation
The application process for the 2026 track began with a global call for entries, drawing 135 innovative firms eager to apply their technologies to the unique challenges of plastic and reconstructive surgery. Applicants were required to demonstrate not only technical viability but also a clear path toward improving patient safety and surgical efficiency.
The Narrowing Field
Following an intensive, multi-layered review process by industry experts, clinicians, and regulatory consultants, the field was winnowed down to 12 finalists. These companies were invited to San Francisco for a live-pitch event, where they faced a panel of judges composed of leading plastic surgeons and medical device venture capitalists.
The Selection
The final five were chosen based on their ability to address specific gaps in current surgical practice, ranging from AI-driven imaging to advanced tissue engineering. These companies are now preparing for the next phase of the program: the "Plastic Surgery The Meeting" showcase, scheduled for October 15–18 in Houston. This event serves as a pivotal moment where these startups will engage in direct dialogue with the surgeons who may eventually utilize their technology on patients.
Supporting Data: A Proven Catalyst for Growth
The collaboration between ASPS and MedTech Innovator is not a fledgling experiment but a proven engine of economic and clinical success. Over the past five years, the program has established a track record that highlights the significant impact of industry-specialist partnerships.
The Five-Year Impact
Since the inception of this specialized track, 18 companies have successfully navigated the ASPS/MTI accelerator. The results speak for themselves:
- Total Capital Raised: These 18 startups have collectively secured over $120 million in funding.
- Market Success: Two of the program’s alumni have already achieved successful exits, signaling the high commercial potential of the technologies incubated.
- Award Recognition: Participants in the ASPS track have collectively secured more than $337,000 in prize money through MTI competitive rounds.
The Broader MTI Ecosystem
The success of the ASPS track is nested within the massive reach of the MedTech Innovator organization. Founded in 2013, MTI has become the world’s largest accelerator for medical technology. To date, the program has supported more than 800 startups, helping them secure over $11 billion in total equity funding. Perhaps most importantly, the program has been a driving force behind more than 500 FDA approvals and authorizations, demonstrating its efficacy in moving ideas from the bench to the bedside.
Official Responses: Aligning Clinical Expertise with Innovation
The leadership at both the ASPS and The Plastic Surgery Foundation (PSF) views this partnership as an essential evolution of the specialty. By embedding themselves in the innovation cycle, plastic surgeons are no longer just end-users of technology—they are active architects of it.
"Plastic surgery has always been a specialty driven by innovation, and the Society’s unique partnership with MedTech Innovator allows us to help shape the next generation of technologies," said Babak Mehrara, MD, president of The Plastic Surgery Foundation.
Dr. Mehrara emphasized that the primary goal of this collaboration is the translation of high-tech concepts into high-quality patient care. "By connecting entrepreneurs with the expertise of plastic surgeons, we’re helping ensure these solutions are developed with patients’ needs in mind while accelerating innovations that have the potential to strengthen patient care across the specialty."
This sentiment is echoed by the leadership at MedTech Innovator, who view the plastic surgery specialty as an ideal proving ground for disruptive health tech. The synergy between MTI’s business-acceleration resources and the ASPS’s clinical wisdom provides a unique "de-risking" environment for investors, ensuring that technologies entering the market have the stamp of clinical approval from the start.
Implications: The Future of Plastic and Reconstructive Surgery
The selection of these five startups signals several key trends that will dominate the industry in the coming decade.
1. The Rise of AI and Digital Health
With companies like FeminAI and ImageAssist in the cohort, it is clear that digital health and Artificial Intelligence are no longer peripheral to surgery; they are becoming core components. AI-driven imaging, for example, promises to improve pre-operative planning and post-operative monitoring, reducing the incidence of complications and improving aesthetic symmetry.
2. Regenerative Medicine and Tissue Engineering
The inclusion of firms like GenesisTissue and GenAssist highlights the industry’s shift toward regenerative medicine. As surgeons seek to move beyond synthetic implants, technologies that encourage the body to heal or reconstruct itself using its own biological materials are gaining massive traction. This is the "Holy Grail" of reconstructive surgery—creating natural-looking, permanent results that integrate seamlessly with the patient’s biology.
3. Precision and Patient Safety
Tissuelock and the broader cohort focus on the mechanics of wound care and tissue integrity. In an era where patient safety is paramount, these technologies provide a layer of precision that can minimize recovery times and decrease the burden on healthcare facilities.
4. The Mentorship Model as a Standard
The program’s success with the "corporate mentorship" model—pairing startup founders with senior industry executives—is creating a blueprint for how medical devices should be developed. By providing individualized guidance, the program ensures that startups avoid the "valley of death" often associated with early-stage medical device development.
Conclusion: A New Era of Surgical Innovation
The 2026 MedTech Innovator cohort representing the ASPS track stands at the intersection of hope and hard science. As these companies refine their technologies, they carry with them the weight of expectations from the global surgical community.
As we look toward the announcements in Boston this fall, the focus remains firmly on the patient. Whether through improved diagnostic clarity, better tissue integration, or AI-driven predictive modeling, the goal of the ASPS-MTI partnership remains constant: to provide plastic surgeons with the most advanced tools to deliver safer, more effective, and more personalized care.
The story of these five companies is just beginning. Over the next year, they will undergo a transformation of their own, evolving from promising startups into the next generation of medical technology leaders. For the plastic surgery specialty, this is not just a competition—it is a roadmap to the future of the operating room.
About MedTech Innovator
Headquartered in Los Angeles, MedTech Innovator is the premier accelerator for the medical technology industry, specializing in devices, digital health, and diagnostics. Its mission is to bridge the gap between innovation and patient health by providing a robust infrastructure of mentorship, venture capital connections, and strategic partnerships. By fostering an environment where clinical necessity meets commercial scalability, MTI continues to set the standard for what it means to innovate in the 21st-century healthcare market. For more information, visit medtechinnovator.org.
